Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection

AIDS

Volumn 14, Issue 6, 2000, Pages 671-681

  Eron, Joseph J ^a,f   Yetzer, Ellen S ^b   Ruane, Peter J ^c   Becker, Stephen ^d   Sawyerr, Gosford A ^e   Fisher, Robin L ^e   Tolson, Jerry M ^e   Shaefer, Mark S ^e  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b Pacific Oaks Medical Group   (United States)

^c Tower Infectious Diseases ^*  (United States)

^d Pacific Horizon Medical Group   (United States)

^e GLAXOSMITHKLINE   (United States)

^f General Clinical Research Center   (United States)

Author keywords

CD4+ cell count; Combination antiretroviral therapy; HIV; Lamivudine; Lamivudine zidovudine combination tablet; Viral load; Zidovudine

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; VIRUS RNA; ZIDOVUDINE;

ADULT; AGED; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD TOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; NEPHROLITHIASIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TABLET; THROMBOPHLEBITIS; TREATMENT FAILURE; VIRUS LOAD;

ADULT; AGED; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; PATIENT COMPLIANCE; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD; ZIDOVUDINE;

EID: 0034104090     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200004140-00006     Document Type: Article

References (29)

1. 1. Hammer S, Squires K, Hughes M, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733.
2. 2. Gulick RM, Mellors JW, Havlir D, et al. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. JAMA 1998, 280:35-41.
3. 3 - 60-week follow-up. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, Illinois, February 1998 [abstract No. 383].
4. 4. Hoen B, Harzic M, Dumon C, et al. Efficacy of zidovudine, lamivudine, and ritonavir combination in patients with symptomatic primary HIV-1 infection: the ANRS 053/53B trial. Can eradication be obtained? Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, Illinois, February 1998 [abstract 524].
5. 5. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998. Updated recommendations of the International AIDS Society-USA Panel. JAMA 1998, 280: 78-86.
6. 6. National Institutes of Health. Report of the NIH panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. www.hivatis.org/guidelines/AAMay599.pdf.
7. 7. Tseng AL-I. Compliance issues in the treatment of HIV infection. Am J Health-Sys Pharm 1998, 55:1817-1824.
8. 8. Eldred LJ, Wu AW, Chaisson RE, Moore RD. Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 18:117-125.
9. 9. Muma RD, Ross MW, Parcel GS, Pollard RB. Zidovudine adherence among individuals with HIV infection. AIDS Care 1995, 7:439-447.
10. 10. Singh N, Squier C, Sivek C, Wagener M, Hong Nguyen M, Yu VL. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care 1996, 8:261-269.
11. 11. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996, 335:1081-1090.
12. 12. Raboud JM, Montaner JSG, Rae S, et al. Predictors of duration of plasma viral load suppression. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, September -October 1997 [abstract A14].
13. 13. Montaner JSG, Raboud JM, Rae S for the INCAS and AVANTI Study Groups. Adherence to treatment increases duration of virologic suppression regardless of pVL nadir 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, California, September 1998 [abstract LB-10].
14. 14. Knobel H, Carmona A, Grau S, Pedro-Botet J, Díez A. Adherence and effectiveness of highly active antiretroviral therapy (letter). Arch Intern Med 1998, 158:1953.
15. 15. Blaschke TF. Noncompliance and resistance to protease inhibitors. Fourth National Conference on Retroviruses and Opportunistic Infections. Washington, DC; January 1997 [abstract S43].
16. 16. Vanhove GR, Schapiro JM, Winters MA, et al. Patient compliance and drug failure in protease inhibitor monotherapy (letter). JAMA 1996, 276:1955-1956.
17. 17. Moore KHP, Shaw S, Laurent AL, et al. Lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with lamivudine and zidovudine administered concurrently and the effect of food on absorption. J Clin Pharmacol 1999, 39:593-605.
18. 18. Childress JK, Jhingran P, Scott-Lennox J, Tolson J. Development and initial evaluation of the Patient Medication Adherence Questionnaire (PMAQ). Presented at the Sixth European Conference on Clinical Aspects and Treatment of HIV Infection. Hamburg, Germany, October 11-15, 1997.
19. 19. Anon. Table for Grading of Adult Adverse Experiences: Washington, DC: National Institute of Allergy and Infectious Diseases, Division of AIDS; August 1992.
20. 20. Food and Drug Administration. E9 statistical principles for clinical trials. Federal Register 1998, 63:49583-49598.
21. 21. Committee for Proprietary Medicinal Products (CPMP) European Working Party. Points to Consider on Biostatistical/methodological Issues arising from Recent CPMP Discussions on Licensing Applications: Superiority, Non-inferiority and Equivalence. London, UK: Committee for Proprietary Medicinal Products (CPMP) European Working Party; September 23, 1999.
22. 22. Rozenbaum W, Chauveau E. Phase 3 study of the antiviral activity of AZT-3TC given as separate regimens versus a new fixed dose combination (Combivir®). Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, Illinois, February 1998 [aAbstract No. 669].
23. 23. Ho DD, Neuman AU, Perelson, AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
24. 24. Mehta S, Moore RD, Graham NMH. Potential factors affecting adherence with HIV therapy. AIDS 1997, 11:1665-1670.
25. 25. Corless IB, Holzemer WL, Turner JG, et al. Cognition and HIV adherence. XIIth International Conference on AIDS. Geneva, Switzerland, June-July 1998 [abstract 32387].
26. 26. Von Bargen J, Moorman A, Holmberg S. How many pills do patients with HIV infection take? [letter]. JAMA 1998, 280:29.
27. 27. Tebas P, Royal M, Fichtenbaum C, et al. Relationship between adherence to HAART and disease state. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, Illinois, February 1998 [abstract 149].
28. 28. Kim HM, Lagakos SW. Assessing drug compliance using longitudinal marker data, with application to AIDS. Stat Med 1994, 13:2141-2153.
29. 29. Frick PA, Gal P, Lane TW, Sewell PC. Antiretroviral medication compliance in patients with AIDS. AIDS Patient Care and STDs 1998, 12:463-470.